Pharmacokinetics and safety of single oral doses of sirolimus (rapamycin) in healthy male volunteers. 2000

C Brattström, and J Säwe, and B Jansson, and A Lönnebo, and J Nordin, and J J Zimmerman, and J T Burke, and C G Groth
Division of Transplantation Surgery, Department of Surgery, Huddinge Hospital, Sweden.

A phase I study was conducted to determine the pharmacokinetics, safety, and tolerability of sirolimus, a new immunosuppressive drug, in 45 healthy men between 19 and 36 years of age. Nine subjects in each group were randomly assigned to receive single oral doses of either sirolimus (n = 6) or placebo (n = 3) in group I (0.3 mg/m2), group II (1 mg/m2), group III (3 mg/m2), group IV (5 mg/m2) and group V (8 mg/m2). No serious adverse events occurred during the study. Twenty-eight of the 45 volunteers (62%) reported an adverse event; 19 of 30 (63%) were in the sirolimus group and 9 of 15 (60%) were in the placebo group (ns). Asthenia was the most common adverse event, occurring in 7 of 30 (23%) in the sirolimus group compared with 6 of 15 (40%) in the placebo group (ns). Absorption occurred within 1 hour in all volunteers. Whole blood peak concentration and area under the concentration-time curve increased proportionally with dose. Mean (+/- SD) whole blood terminal disposition half-life (t1/2), apparent oral dose clearance (Cl/F), and volume of distribution (Vss/F) were 82 +/- 12 hours, 278 +/- 117 mL/h x kg and 23 +/- 10 L/kg, respectively. Distribution of sirolimus into formed blood elements was extensive, with a mean whole blood-to-plasma ratio of 36. Single oral doses of sirolimus (0.3 to 8 mg/m2) solution were well tolerated in healthy male volunteers.

UI MeSH Term Description Entries
D007166 Immunosuppressive Agents Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging. Immunosuppressant,Immunosuppressive Agent,Immunosuppressants,Agent, Immunosuppressive,Agents, Immunosuppressive
D008297 Male Males
D012016 Reference Values The range or frequency distribution of a measurement in a population (of organisms, organs or things) that has not been selected for the presence of disease or abnormality. Normal Range,Normal Values,Reference Ranges,Normal Ranges,Normal Value,Range, Normal,Range, Reference,Ranges, Normal,Ranges, Reference,Reference Range,Reference Value,Value, Normal,Value, Reference,Values, Normal,Values, Reference
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004311 Double-Blind Method A method of studying a drug or procedure in which both the subjects and investigators are kept unaware of who is actually getting which specific treatment. Double-Masked Study,Double-Blind Study,Double-Masked Method,Double Blind Method,Double Blind Study,Double Masked Method,Double Masked Study,Double-Blind Methods,Double-Blind Studies,Double-Masked Methods,Double-Masked Studies,Method, Double-Blind,Method, Double-Masked,Methods, Double-Blind,Methods, Double-Masked,Studies, Double-Blind,Studies, Double-Masked,Study, Double-Blind,Study, Double-Masked
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D019540 Area Under Curve A statistical means of summarizing information from a series of measurements on one individual. It is frequently used in clinical pharmacology where the AUC from serum levels can be interpreted as the total uptake of whatever has been administered. As a plot of the concentration of a drug against time, after a single dose of medicine, producing a standard shape curve, it is a means of comparing the bioavailability of the same drug made by different companies. (From Winslade, Dictionary of Clinical Research, 1992) AUC,Area Under Curves,Curve, Area Under,Curves, Area Under,Under Curve, Area,Under Curves, Area

Related Publications

C Brattström, and J Säwe, and B Jansson, and A Lönnebo, and J Nordin, and J J Zimmerman, and J T Burke, and C G Groth
January 1994, Journal of cardiovascular pharmacology,
C Brattström, and J Säwe, and B Jansson, and A Lönnebo, and J Nordin, and J J Zimmerman, and J T Burke, and C G Groth
January 2005, Clinical drug investigation,
C Brattström, and J Säwe, and B Jansson, and A Lönnebo, and J Nordin, and J J Zimmerman, and J T Burke, and C G Groth
December 2014, International journal of clinical pharmacology and therapeutics,
C Brattström, and J Säwe, and B Jansson, and A Lönnebo, and J Nordin, and J J Zimmerman, and J T Burke, and C G Groth
February 2006, Therapeutic drug monitoring,
C Brattström, and J Säwe, and B Jansson, and A Lönnebo, and J Nordin, and J J Zimmerman, and J T Burke, and C G Groth
July 1996, Journal of clinical pharmacology,
C Brattström, and J Säwe, and B Jansson, and A Lönnebo, and J Nordin, and J J Zimmerman, and J T Burke, and C G Groth
October 2004, Biopharmaceutics & drug disposition,
C Brattström, and J Säwe, and B Jansson, and A Lönnebo, and J Nordin, and J J Zimmerman, and J T Burke, and C G Groth
January 2015, Drug design, development and therapy,
C Brattström, and J Säwe, and B Jansson, and A Lönnebo, and J Nordin, and J J Zimmerman, and J T Burke, and C G Groth
January 1988, International journal of clinical pharmacology research,
C Brattström, and J Säwe, and B Jansson, and A Lönnebo, and J Nordin, and J J Zimmerman, and J T Burke, and C G Groth
January 1992, Pharmacotherapy,
C Brattström, and J Säwe, and B Jansson, and A Lönnebo, and J Nordin, and J J Zimmerman, and J T Burke, and C G Groth
March 2006, Journal of clinical pharmacology,
Copied contents to your clipboard!